

# Jean-Guillaume Dillinger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2683903/publications.pdf>

Version: 2024-02-01

35  
papers

1,141  
citations

567281

15  
h-index

454955

30  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1953  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deleterious synergistic effects of acute heart failure and diabetes mellitus in patients with acute coronary syndrome: Data from the FAST-MI Registries. Archives of Cardiovascular Diseases, 2022, , .	1.6	0
2	Coronary Computed Tomography Angiography Analysis of Calcium Content to Identify Non-culprit Vulnerable Plaques in Patients With Acute Coronary Syndrome. Frontiers in Cardiovascular Medicine, 2022, 9, 876730.	2.4	5
3	Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine, 2021, 88, 105122.	1.6	30
4	Antithrombotic strategies in elderly patients with acute coronary syndrome. Archives of Cardiovascular Diseases, 2021, 114, 232-245.	1.6	2
5	Benefits of Ticagrelor Plus Aspirin According to Diabetes-Related Factors. Journal of the American College of Cardiology, 2021, 77, 2378-2381.	2.8	1
6	Impact of BMI on prevalence of coronary atherosclerotic lesions in non-smoking premenopausal diabetic women: A monocentric study. Diabetes and Metabolism, 2021, 47, 101218.	2.9	0
7	Is platelet function testing at the acute phase under P2Y12 inhibitors helpful in predicting bleeding in real-life patients with acute coronary syndrome? The AVALANCHE study. Archives of Cardiovascular Diseases, 2021, 114, 612-623.	1.6	0
8	Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. New England Journal of Medicine, 2021, 385, 297-308.	27.0	172
9	Risque de maladie thromboembolique veineuse dans la polyarthrite rhumatoïde. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 338-345.	0.0	0
10	Elevated Brain Natriuretic Peptide and High Brachial Pulse Pressure in Patients With Diabetes. American Journal of Hypertension, 2021, , .	2.0	4
11	Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. Lancet, The, 2020, 396, 1737-1744.	13.7	75
12	Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health, The, 2020, 5, e536-e542.	10.0	169
13	Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. American Heart Journal, 2020, 225, 27-37.	2.7	6
14	Immediate coronary angiogram in out-of-hospital cardiac arrest patients with non-shockable initial rhythm and without ST-segment elevation " Is there a clinical benefit?. Resuscitation, 2020, 155, 226-233.	3.0	8
15	Microcatheter-Facilitated Primary Angioplasty in ST-Segment Elevation Myocardial Infarction. Canadian Journal of Cardiology, 2018, 34, 23-30.	1.7	2
16	Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. Blood Reviews, 2018, 32, 272-279.	5.7	17
17	Prognostic impact of prepercutaneous coronary intervention TIMI flow in patients with ST-segment and non-ST-segment elevation myocardial infarction: Results from the FAST-MI 2010 registry. Archives of Cardiovascular Diseases, 2018, 111, 101-108.	1.6	17
18	Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. Archives of Cardiovascular Diseases, 2018, 111, 85-94.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Improving cannulation time for extracorporeal life support in refractory cardiac arrest of presumed cardiac cause – Comparison of two percutaneous cannulation techniques in the catheterization laboratory in a center without on-site cardiovascular surgery. <i>Resuscitation</i> , 2018, 122, 69-75.	3.0	23
20	Activated Clotting Time to Guide Heparin Dosing in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention and Treated With IIb/IIIa Inhibitors. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006084.	3.9	7
21	P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2016, 116, 369-378.	3.4	97
22	Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. <i>Resuscitation</i> , 2016, 105, 16-21.	3.0	10
23	High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. <i>Thrombosis Research</i> , 2016, 144, 56-61.	1.7	7
24	Accuracy of point of care coagulometers compared to reference laboratory measurements in patients on oral anticoagulation therapy. <i>Thrombosis Research</i> , 2016, 140, 66-72.	1.7	11
25	Predictors of High On-Aspirin Platelet Reactivity in High-Risk Vascular Patients Treated With Single or Dual Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2015, 115, 1305-1310.	1.6	13
26	Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. <i>Hypertension</i> , 2015, 66, 1138-1144.	2.7	38
27	Favourable 5-year postdischarge survival of comatose patients resuscitated from out-of-hospital cardiac arrest, managed with immediate coronary angiogram on admission. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2014, 3, 183-191.	1.0	32
28	Ticagrelor effectiveness overestimated by VASP index. <i>International Journal of Cardiology</i> , 2014, 176, 557-559.	1.7	14
29	Letter by Dillinger et al Regarding Article, “Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin”. <i>Circulation</i> , 2013, 128, e189.	1.6	0
30	Monitoring Persistent Platelet Reactivity in Patients with Unprotected Left Main Stenting. <i>Journal of Interventional Cardiology</i> , 2013, 26, 578-585.	1.2	4
31	Role of cardiac troponin in the diagnosis of acute myocardial infarction in comatose patients resuscitated from out-of-hospital cardiac arrest. <i>Resuscitation</i> , 2012, 83, 452-458.	3.0	44
32	Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocytemia. <i>Thrombosis Research</i> , 2012, 129, 91-94.	1.7	58
33	Common mechanisms for calorie restriction and adenylyl cyclase type 5 knockout models of longevity. <i>Aging Cell</i> , 2012, 11, 1110-1120.	6.7	27
34	Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. <i>American Heart Journal</i> , 2012, 164, 600-606.e1.	2.7	95
35	24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2011, 105, 336-344.	3.4	124